A rare case report of ovarian juvenile granulosa cell tumor with massive ascites as the first sign, and review of literature

Ma, Liang; Zhang, Liwen; Yun, Zhong; Yanbo, Ding; Chen, Jianping

doi:10.1097/md.0000000000010916

Cited by 9 publications

(6 citation statements)

References 21 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They are common presentation in epithelial ovarian tumors, and rarely reported among AOGCT. (33)(34)(35)(36) Studies on Ascites and tumour marker CA125 among AOGCT are scarce, on the other hand, presence of ascites is a sign of higher stage, which was validated in literature as a strong prognostic factor for survival as mentioned above. While high CA125…”

Section: Discussionmentioning

confidence: 81%

Adult-type ovarian granulosa cell tumour: Treatment Outcomes from a Single Institutional Experience

Badran

Elshenawy

Soudy

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Ovarian granulosa cell tumour is rare. This study aim is to report the clinical characteristics and long-term outcomes of adult-type OGCT (AOGCT) at King Faisal Specialist Hospital and Research Centre ( KFSH&RC) and to determine the prognostic factors affecting relapse and survival. we retrospectively reviewed patients with AOGCT, from 1988 to 2014, who were treated at our institution. Baseline characteristics, pathological findings, and outcomes were analysed, and reported. RESULTS: Sixty-one patients with AOGCT were identified with a median age of 49 years. Median follow-up was 5.0 years (range 2.1 -8.2 years). 74% of patients were FIGO stage I, whereas 7% stage II, 5% stage III and unknown in 14%. The most common presenting symptoms included abdominal pain (43%) and vaginal bleeding (43%). The majority of patients (38 patients, 62%) were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy. Five (8%) patients received adjuvant chemotherapy. Sixteen patients (26%) relapsed with a median time to relapse of 5.5 years (0.7-8.1 years). Half of the recurrences (8 patients, 50%) occurred after 5 years of diagnosis. Five-year overall survival and disease-free survival were 93% and 84%, respectively. Factors associated with high risk of recurrence were presence of ascites (p=0.000) and elevated preoperative CA 125 level (p=0.048). The overall survival was significantly influenced by the menopausal status (premenopausal 100% vs. postmenopausal 84%; p=0.02), preoperative CA 125 (normal 100% vs. elevated 64%; p=0.005), Ascites (present 33% vs. absent 100%; p=0.000), and age (<55 years 100% vs. ≥ 55 years 77%; p= 0.002). CONCLUSION: This study confirms a good outcome of patients with AOGCT. They require long-term follow-up because the recurrence can occur many years post the definitive therapy. The presence of ascites and elevated preoperative CA 125 levels were associated with a higher risk of recurrence and poor prognosis. The outcome seems not to be affected by fertility-sparing surgery and/or adjuvant chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 81%

Adult-type ovarian granulosa cell tumour: Treatment Outcomes from a Single Institutional Experience

Badran

Elshenawy

Soudy

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Ascites and high tumour marker (CA125) were found to be the most important two independent factors for recurrence with an impact on survival as well. They are common presentations in epithelial ovarian tumours and are rarely reported in patients with AOGCT [35][36][37][38]. Studies on ascites and tumour marker CA125 among AOGCT are scarce.…”

Section: Discussionmentioning

confidence: 99%

Adult-Type Ovarian Granulosa Cell Tumour: Treatment Outcomes From a Single-Institution Experience

Alhusaini¹,

Elshenawy²,

Badran³

et al. 2022

Cureus

View full text Add to dashboard Cite

Objectives: Ovarian granulosa cell tumour is rare. This study aims to report the clinical characteristics and long-term outcomes of adult-type ovarian granulosa cell tumour (AOGCT) at King Faisal Specialist Hospital and Research Centre (KFSH&RC) and to determine the prognostic factors affecting relapse and survival.Methods: We retrospectively reviewed patients with AOGCT, from 1988 to 2014, who were treated at our institution. Baseline characteristics, pathological findings, and outcomes were analysed and reported.Results: Sixty-one patients with AOGCT were identified with a median age of 49 years. Median follow-up was 5.0 years (range 2.1-8.2 years). 74% of patients were FIGO (International Federation of Gynecology and Obstetrics) stage I, whereas 7% were stage II, 5% were stage III, and unknown in 14% of the cases. The most common presenting symptoms included abdominal pain (43%) and vaginal bleeding (43%). The majority of patients (38 patients, 62%) were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy. Five (8%) patients received adjuvant chemotherapy. Sixteen patients (26%) relapsed with a median time to relapse of 5.5 years (0.7-8.1 years). Half of the recurrences (eight patients, 50%) occurred after five years of diagnosis. Five-year overall survival and disease-free survival (DFS) were 93% and 84%, respectively. Factors associated with a high risk of recurrence were the presence of ascites (p=0.000) and elevated preoperative CA 125 level (p=0.048). The overall survival was significantly influenced by the menopausal status (premenopausal 100% vs. postmenopausal 84%; p=0.02), preoperative CA 125 (normal 100% vs. elevated 64%; p=0.005), ascites (present 33% vs. absent 100%; p=0.000), and age (<55 years 100% vs. ≥ 55 years 77%; p= 0.002). Conclusion:This study confirms a good outcome for patients with AOGCT. They require long-term follow-up as late recurrences can occur many years post definitive therapy. The presence of ascites and elevated preoperative CA 125 levels were associated with a higher risk of recurrence and poor prognosis. Outcomes appear unaffected by fertility-sparing surgery or adjuvant chemotherapy.

show abstract

“…Sin embargo, en este caso, la paciente solo presentó aumento de volumen de la circunferencia abdominal, condicionado por la ascitis masiva y el tumor ovárico. Se encontró el reporte de un caso similar con ascitis masiva, como primer signo de presentación de TCGJ en una adolescente (16).…”

Section: Discussionunclassified

Tumor de células de la granulosa juvenil de ovario. Presentación inusual. Reporte de un caso

Lara¹,

Ruggiero²,

Silva³

et al. 2021

RSOGV

View full text Add to dashboard Cite

Granulose cell tumors represent 2% of ovarian tumors. They are classified as adult type and juvenile type. The juvenile type is associated with precocious pseudopuberty, irregular menstruation or nonspecific symptoms such as abdominal pain and palpable mass. More than 95% are confined to the ovary. A case of a 31-year-old patient is described. The patient consulted for 6-month evolution of increased abdominal volume and weight loss. Right ovary tumor was diagnosed. Tumor excision by gynecological laparotomy with positive frozen cut biopsy and surgical staging were performed. Pathological anatomy reported stromal tumor, and sexual cords suggestive of malignant juvenile granulose cell tumor. Immunohistochemistry reported positive inhibin B. It was concluded as stage IIIA2. This is a rare neoplasm with variable behavior. Accurate diagnosis is based on histological and immunohistochemical studies. Key words: Granulosa, Cell tumor, Juvenile granulosa cell tumor, Ascites, Diagnosis.

show abstract

A rare case report of ovarian juvenile granulosa cell tumor with massive ascites as the first sign, and review of literature

Cited by 9 publications

References 21 publications

Adult-type ovarian granulosa cell tumour: Treatment Outcomes from a Single Institutional Experience

Adult-type ovarian granulosa cell tumour: Treatment Outcomes from a Single Institutional Experience

Adult-Type Ovarian Granulosa Cell Tumour: Treatment Outcomes From a Single-Institution Experience

Tumor de células de la granulosa juvenil de ovario. Presentación inusual. Reporte de un caso

Contact Info

Product

Resources

About